Inadequate response or intolerability to oral methotrexate: Is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics?-Reference-Cited by-同舟云学术

Inadequate response or intolerability to oral methotrexate: Is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics?

Published:2016-03-02 Issue:5 Volume:36 Page:627-633
ISSN:0172-8172
Container-title:Rheumatology International
language:en
Short-container-title:Rheumatol Int

Author:

Yadlapati Sujani,Efthimiou Petros

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s00296-016-3447-x.pdf

Reference29 articles.

1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O’Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(5):625–639. doi: 10.1002/acr.21641

2. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964–975. doi: 10.1136/ard.2009.126532

3. Chiaravalloti AJ, Strober BE (2014) The use of self-administered subcutaneous methotrexate for the treatment of psoriasis. J Drugs Dermatol 13(8):929–931

4. Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R (2014) Methotrexate: an old new drug in autoimmune disease. Expert Rev Clin Immunol 10(11):1519–1530. doi: 10.1586/1744666x.2014.962996

5. Striesow F, Brandt A (2012) Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation. Ther Adv Musculoskelet Dis 4(1):3–9. doi: 10.1177/1759720x11431004

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subcutaneous injection of methotrexate: Advantages in the treatment of rheumatoid arthritis;Modern Rheumatology;2022-12-16

2. The effects of drug transporters on the efficacy of methotrexate in the treatment of rheumatoid arthritis;Life Sciences;2021-03

3. Non-adherence and discontinuation rate for oral and parenteral methotrexate: A retrospective-cohort study in 8,952 patients with psoriatic arthritis;Journal of Translational Autoimmunity;2021

4. Prefilled pen versus prefilled syringe: a pilot study evaluating two different methods of methotrexate subcutaneous injection in patients with JIA;Pediatric Rheumatology;2020-08-12

5. Recomendaciones sobre el uso de metrotexato parenteral en enfermedades reumáticas;Reumatología Clínica;2018-05